RNLXYOTCServices-Medical LaboratoriesFiscal year ends June 30Also trades as RENXF
Renalytix plc
Financials through Q1 FY2025, quarter ended Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$3.56+0.06 (+1.57%)
Close on Oct 19, 2026
- Market cap
- $375.75M
- P/E (TTM)
- –
- Dividend yield
- –
Renalytix plc income statement
Ratios
Latest available, balances at Sep 30, 2024
Profitability, TTM
- Gross margin
- 12.7%
- Operating margin
- -1054.9%
- Net margin
- -1191.8%
- Return on equity, FY2024
- 7543.6%
Financial strength
- Current ratio
- 0.24
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 7.6%
Valuation
- P/E ratio
- –
- Price to sales
- 159.76
- Price to book
- –
- Dividend yield
- –